Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237122 | 0.87 | ESRRG (0.40) | ESRRGCTSKLTB4RLTB4R2PDK2 | |
| SCHEMBL19878813 | 0.86 | HTR2C (0.39) | L3MBTL1HTR2CSLC6A4 | |
| SCHEMBL30264506 | 0.82 | LTB4R (0.46) | ESRRGCTSKL3MBTL1LTB4RLTB4R2 | |
| SCHEMBL2240309 | 0.82 | PPARA (0.44) | ESRRGCTSKLTB4RLTB4R2PDK2 | |
| SCHEMBL3015417 | 0.82 | ESRRG (0.56) | ESRRGL3MBTL1LTB4RLTB4R2PDK2 | |
| SCHEMBL30954590 | 0.81 | AOC3 (0.47) | ESRRGL3MBTL1PPARAPPARG | |
| SCHEMBL21996922 | 0.81 | ESRRG (0.42) | ESRRGCTSKLTB4RLTB4R2PDK2 | |
| SCHEMBL22777273 | 0.81 | ESRRG (0.42) | ESRRGCTSKLTB4RLTB4R2PDK2 | |
| SCHEMBL1129151 | 0.81 | TAAR1 (0.50) | ESRRGCTSKLTB4RLTB4R2PDK2 | |
| SCHEMBL30954592 | 0.81 | AOC3 (0.47) | ESRRGL3MBTL1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | ESRRG 1518/4885CTSK 2843/4885L3MBTL1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.